Diadema Partners LP Acquires Shares of 101,502 GH Research PLC (NASDAQ:GHRS)

Diadema Partners LP bought a new stake in GH Research PLC (NASDAQ:GHRS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 101,502 shares of the company's stock, valued at approximately $711,000. Diadema Partners LP owned about 0.20% of GH Research as of its most recent SEC filing.

Separately, Geode Capital Management LLC grew its holdings in GH Research by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock valued at $508,000 after purchasing an additional 3,092 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research Stock Up 0.3 %

GHRS stock traded up $0.03 during midday trading on Friday, reaching $9.53. 83,428 shares of the company's stock traded hands, compared to its average volume of 173,193. The company has a 50-day simple moving average of $10.54 and a two-hundred day simple moving average of $9.65. GH Research PLC has a 1-year low of $6.00 and a 1-year high of $20.50. The company has a market cap of $495.83 million, a price-to-earnings ratio of -12.06 and a beta of 0.84.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. Equities research analysts forecast that GH Research PLC will post -0.8 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GHRS shares. Guggenheim started coverage on shares of GH Research in a research note on Thursday, March 13th. They issued a "buy" rating and a $32.00 target price on the stock. Stifel Nicolaus lifted their price objective on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Royal Bank of Canada assumed coverage on GH Research in a report on Friday, March 7th. They issued an "outperform" rating and a $31.00 target price on the stock. Cantor Fitzgerald began coverage on GH Research in a research report on Thursday, February 13th. They issued an "overweight" rating and a $14.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of GH Research in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, GH Research has an average rating of "Buy" and an average target price of $30.86.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).